This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
| Feature | TOTAL |
|---|---|
| NCT ID | NCT01149044 |
| Design | Randomized, parallel assignment |
| Masking | None |
| Primary purpose | Treatment |
| Condition | Acute Coronary Syndrome; ST Elevation Myocardial Infarction; Percutaneous Coronary Intervention |
| Intervention | Percutaneous Coronary Intervention with or without manual aspiration thrombectomy |
2. Clinical Question
Population
Patients with ST-segment elevation myocardial infarction undergoing primary PCI.
Intervention
PCI with routine aspiration thrombectomy.
Comparator
PCI alone.
Primary Question
Does routine aspiration thrombectomy alter the occurrence of the primary cardiovascular composite endpoint?
3. Trial Design
The registry describes TOTAL as a randomized, parallel-assignment trial with two intervention groups and no masking. The trial began in 2010-08 and reached primary completion in 2015-03.
| Design Element | Description |
|---|---|
| Allocation | Randomized |
| Model | Parallel |
| Arms | 2 |
| Sponsor | Population Health Research Institute |
4. Endpoints
| Endpoint | Time Frame |
|---|---|
| The first occurrence of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or new or worsening NYHA Class IV heart failure | Up to 180 days |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary endpoint as a composite time-to-event cardiovascular outcome measured through 180 days. For an endpoint combining clinical events over follow-up, statistical analysis would typically compare event occurrence between randomized groups using time-to-event methods that account for varying follow-up and censoring.
6. Statistical Methodology
Composite clinical endpoints
A composite endpoint combines multiple clinically important events into one outcome. This can increase statistical efficiency because more events contribute to the analysis, but interpretation depends on the frequency and clinical importance of each component.
Time-to-event analysis
When outcomes are measured over time, analysis generally accounts for both whether an event occurs and when it occurs. Patients without an observed event during follow-up may contribute censored observations.
Randomization and comparative inference
Randomization creates the basis for comparing treatment groups because assignment is determined by the trial design rather than clinical characteristics that might influence outcomes.
7. Statistical Methods Explained
Why use a composite endpoint?
A composite endpoint allows several clinically meaningful outcomes to be evaluated together. The interpretation depends on understanding each component and its contribution to the overall result.
Why does randomization matter?
Randomization helps balance measured and unmeasured characteristics between groups, supporting a causal comparison of assigned interventions.
What does a 180-day endpoint mean?
The registry defines the primary outcome assessment window as up to 180 days after trial enrollment or treatment assignment.
Why are censoring methods important?
Some participants may not experience the endpoint during observed follow-up. Time-to-event methods incorporate available follow-up information while accounting for incomplete event observation.
8. Limitations
- The registry does not report posted statistical analyses for the primary endpoint.
- Without posted estimates, confidence intervals, event counts, or p-values, treatment-effect magnitude cannot be evaluated from the registry record alone.
- Composite endpoints require interpretation of both the overall outcome and the individual clinical events included.
9. Why This Trial Matters Statistically
| Concept | Application |
|---|---|
| Randomization | Randomized comparison of two PCI strategies |
| Composite endpoints | Multiple cardiovascular outcomes combined into one primary endpoint |
| Time-to-event methods | Appropriate framework for events occurring during follow-up |
| Clinical interpretation | Requires understanding both statistical and clinical components of outcomes |
10. Limitations and Interpretation Issues
The registry provides the design and endpoint framework but does not provide posted statistical analyses. Therefore, the comparative effect estimate, uncertainty interval, and formal hypothesis-test result are not available from the registry record.